LigaTrap® Technologies has developed a novel, patented portfolio of affinity ligands specific for the purification of monoclonal and polyclonal immunoglobulins from various species. In addition to species-specific ligands, advantages include the ability to elute bound antibodies at a milder pH (pH 4.0) than proteins A and G (pH ≤ 3.0), thus reducing the potential for precipitation and inactivation of pH sensitive antibodies. Our goal is to generate high purity antibodies using ligands superior to those currently available in the marketplace. The LigaTrap® Team has performed extensive side-by-side testing with purification products that are currently on the market. The LigaTrap® Team has also expanded our capabilities to include our expert Process Development and Downstream Optimization Services.
LigaTrap® is actively partnering with technologies and platforms that are rapidly expanding in the Therapeutics Industry.